4-year experience with percutaneous US-guided radiofrequency ablation of kidney tumors

4-year experience with percutaneous US-guided radiofrequency ablation of kidney tumors

Communities & Collections

4-year experience with percutaneous US-guided radiofrequency ablation of kidney tumors

Bibliographic description

title:	4-year experience with percutaneous US-guided radiofrequency ablation of kidney tumors
author:	Salagierska-Barwińska Anna, Salagierski Marek, Salagierski Maciej
journal title:	Polish Journal of Radiology
volume:	72
issue:	2
date of publication :	2007
pages:	32-35
article ID:	478067
ISSN:	1733-134X
eISSN:	1899-0967
URL:	http://archiwum.inforadiologia.pl/download/index/idArt/478067.html
date accessed:	2019-06-06
notes:	Bibliogr. s. 35
language:	English
journal language:	English
abstract in English:	Background: The past decades have significantly changed the diagnosis and management of kidney tumors. There is a growing trend for a less invasive therapeutic approach. The study seeks to present our experience with a number of patients who underwent percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) of renal masses. Material/Methods: From July 2002 to December 2006, RFA was carried out in 55 selected patients with an enhancing kidney tumor on computed tomography (CT). The procedure was performed under conscious sedation. The patients were at risk for surgery or had a remaining kidney. Monopolar Cool-tip Tyco or bipolar Celon Olympus RFA devices under US-guidance (convex 3.5 MHz) were used. Abdominal 3-phase multi-slice computed tomography (MSCT) was performed 3, 6 and 12 months post RFA and once yearly thereafter. Results: At a mean follow up of 25 months (range, 6-53 months), 52 of the 55 tumors showed no contrast enhancement on CT. Three incompletely ablated tumors were successfully treated with the second RFA. There were no major complications in any procedure and intervention was well tolerated. So far we have observed one metastasis to a homolateral adrenal gland which was revealed on MSCT. Conclusions: Percutaneous RFA is a minimally invasive technique which appears to be a promising alternative for patients with small renal tumors. 3-phase MSCT improves the imaging of renal masses, enabling not only optimal treatment planning but also a reliable monitoring of tumor destruction after RFA.
keywords in English:	minimally invasive technique, renal tumor, radiofrequency ablation
type:	journal article
subtype:	academic paper

Files in this item

Name: salagierska-barwi ...

Size: 560.8Kb

Format: PDF

View/Open

Name: salagierska-barwi ...

Size: 68.71Kb

Format: OpenOffice Writer

View/Open

This item appears in the following Collection(s)

Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa

Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa